FHA Perspectives 2018-03-23T23:46:13+00:00

Forest, Richter Schizophrenia Drug Met Clinical Trial Goals

0 Comments

Feb. 28 (Bloomberg) --Gedeon Richter Nyrt. (RICHT) and Forest Laboratories Inc. (FRX) said that the experimental antipsychotic drug cariprazine met the goals of two late-stage clinical trials for the [...]

Beyond Competitive Advantage – Who should be trusted to distribute a product requiring a REMS?

0 Comments

As discussed in the New England Journal of Medicine on April 17, 2014 by Sarpatwari, Avorn, and Kesselheim, REMS are being used as a source of [...]

Postmarketing Safety Data Drives Significant Value Even in the Absence of Identified Signals – Part 1 of 3

0 Comments

This is the first of a three part series on the value of disclosure of postmarketing safety information by pharmaceutical manufacturers. Spontaneous postmarketing safety data is [...]

Outsourcing Best Practices

0 Comments

Outsourcing is a part of our daily reality in the pharmaceutical industry.  Both pharmacovigilance and medical affairs are utilizing outsourced resources to a greater and greater [...]

Guide to surviving the digital age as consumers obtain safety information online

0 Comments

A double-edged reality of the digital age:  most healthcare consumers get their drug safety information from the internet. Physicians and pharmacists must be prepared to address [...]